---

---

tags : Presentation    exchanges : Nasdaq   

save search

---

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-16 (Crawled : 15:00) - ir.auriniapharma.com
AUPH | $5.06 0.4% 430K |

Health Technology

| 0.0% | O: -0.6% H: 0.0% C: 0.0%
conference presentation

---

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
RNXT | $1.15 11K |

| Email alert Add to watchlist
presentation meeting

---

Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
RDUS | $17.25 -1.99% 61K |

Health Technology

| 0.0% | O: -3.32% H: 0.0% C: 0.0%
osteoarthritis congress world presentation tymlos

---

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2024-04-15 (Crawled : 14:00) - globenewswire.com
IMMX | $2.65 -0.38% 120K |

| -3.62% | O: 1.09% H: 1.79% C: -4.66%
nxc-201 presentation cell biopharma for meeting therapy

---

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
CRBU | $4.035 -0.86% 710K |

Health Technology

| -3.1% | O: -0.71% H: 5.27% C: -2.4%
presentation cell meeting therapy

---

Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN P 3 d | $2.67 -8.87% 1.6M |

| 73.37% | O: 41.42% H: 42.68% C: 22.59%
conference disease association alzheimer’s presentation international research for trial

---

Hillman Sets First Quarter 2024 Earnings Release and Results Presentation Date
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
HLMN | $9.58 -0.52% 180K |

| -2.53% | O: 0.3% H: 0.05% C: -2.83%
first presentation results

---

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
TGTX | $14.01 -1.06% 780K |

Health Technology

| -4.48% | O: -3.94% H: 3.0% C: -0.57%
briumvi neurology presentation sclerosis for meeting therapeutics

---

TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
TFFP | $3.85 22K |

Health Technology

| -11.34% | O: 0.25% H: 1.26% C: -11.56%
tacrolimus presentation positive sessions pharmaceuticals trial

---

Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
PVCT | $0.1675 52K |

Manufacturing

| -1.3% | O: 0.0% H: 17.21% C: 7.19%
pv-10 presentation cancer immunotherapy for meeting

---

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
Published: 2024-04-11 (Crawled : 12:00) - phiopharma.com
PHIO | $0.6656 2.3K |

Health Technology

| -2.4% | O: 3.8% H: 1.15% C: -1.19%
presentation cell pharmaceuticals meeting therapy

---

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
TLSA | $0.53 20.46% 79K |

Health Technology

| 14.92% | O: 1.15% H: 9.66% C: 3.34%
life presentation foralumab sciences meeting imaging platform

---

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Published: 2024-04-10 (Crawled : 12:30) - prnewswire.com
MBRX | $4.355 -2.35% 5.7K |

Health Technology

| -14.72% | O: 8.8% H: 3.87% C: -8.61%
presentation positive

---

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - prnewswire.com
FUSN | $21.25 -0.14% 370K |

Health Technology

| -0.47% | O: -0.19% H: 0.28% C: 0.09%
fpi-2265 presentation pharmaceuticals meeting trial

---

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
STTK | $9.025 -3.37% 96K |

Health Technology

| 1.0% | O: -1.11% H: 9.78% C: 9.66%
association presentation cancer research preclinical for meeting

---

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
TRVI | $2.77 -5.14% 40K |

Health Technology

| -8.32% | O: 2.77% H: 1.59% C: -8.57%
conference presentation international therapeutics

---

Invitation presentation of Boliden's Q1 2024 report
Published: 2024-04-09 (Crawled : 11:00) - prnewswire.com
BDNNY | $63.25 5.1K |

n/a

| 0.24% | O: 3.55% H: 0.4% C: -0.35%
report presentation

---

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
THTX | $1.42 7.1K |

Health Technology

| -4.96% | O: 4.96% H: 4.05% C: 4.05%
presentation preclinical platform

---

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
BDTX A | $5.28 1.15% 150K |

Health Technology

| 4.82% | O: 5.22% H: 3.44% C: 2.1%
bdtx-1535 association presentation cancer research for meeting therapeutics

---

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $7.17 0.7% 110K |

Health Technology

| -1.04% | O: 3.27% H: 0.13% C: -4.17%
association presentation cancer cell research meeting skin trial results

---

Gainers vs Losers

53%

47%

Top 10 Gainers

WISA 4 | $7.86 349.14% 120M |

Electronic Technology

TPET | $0.4951 114.24% 29M |

n/a

PRSO | $1.99 56.69% 52M |

Manufacturing

PALI | $6.5 56.25% 22M |

Manufacturing

JAGX | $0.1767 48.74% 430M |

Health Technology

SXTC | $2.03 45.0% 27M |

Health Technology

SPCB | $0.3888 40.87% 27M |

Electronic Technology

DYNT | $0.52 40.39% 20M |

Health Technology

SNGX | $0.54 39.86% 7.3M |

Health Technology

BSGM | $1.53 39.09% 2.6M |

Health Technology

---

Your saved searches

---